Karo Pharma AB Logo

Karo Pharma AB

Develops and sells everyday healthcare products, focusing on OTC and skin health in Europe.

KARO | ST

Overview

Corporate Details

ISIN(s):
NO0010308240 (+4 more)
LEI:
213800G54Z51LOPGTA79
Country:
Sweden
Address:
BOX 16184, 103 24 STOCKHOLM
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Karo Healthcare (formerly Karo Pharma AB) is a healthcare company focused on providing 'smart choices for everyday healthcare.' The company develops, acquires, and commercializes a diverse portfolio of branded products, including over-the-counter (OTC) medicines, consumer health goods, and prescription pharmaceuticals, with a strategic emphasis on skin health. Its mission is to empower consumers to prevent illness and treat common health problems. Karo Healthcare's products are available in over 90 countries, with Europe and the Nordic region serving as its core markets. The company pursues growth through a consumer-centric, omnichannel strategy, combining organic innovation with strategic acquisitions to expand its brand portfolio and global presence.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2022-05-31 16:00
Post-Annual General Meeting Information
Kommuniké från Karo Pharmas årsstämma 2022
Swedish 1.4 MB
2022-05-27 16:00
Pre-Annual General Meeting Information
Ändringar i Karo Intressenter AB:s förslag avseende val av styrelse till Karo P…
Swedish 1.1 MB
2022-05-02 18:30
Pre-Annual General Meeting Information
KALLELSE TILL ÅRSSTÄMMA I KARO PHARMA AKTIEBOLAG
Swedish 4.9 MB
2022-04-19 08:30
Share Issue/Capital Change
Karo Pharmas företrädesemission fulltecknad
Swedish 3.6 MB
2022-04-19 08:30
Share Issue/Capital Change
Karo Pharma’s rights issue fully subscribed
English 3.6 MB
2022-04-01 13:30
M&A Activity
Karo Pharma slutför förvärvet av E45® från Reckitt
Swedish 21.3 KB
2022-04-01 13:30
M&A Activity
Karo Pharma completes the acquisition of the E45® brand from Reckitt
English 46.1 KB
2022-03-23 12:00
Delisting Announcement
Karo Pharma offentliggör prospekt avseende företrädesemissionen och erhåller go…
Swedish 460.3 KB
2022-03-23 12:00
Report Publication Announcement
Karo Pharma publishes prospectus relating to the rights issue and receives appr…
English 438.3 KB
2022-03-16 08:00
Share Issue/Capital Change
Karo Pharma resolves on a fully guaranteed rights issue of approximately SEK 2.…
English 156.1 KB
2022-03-16 08:00
Share Issue/Capital Change
Karo Pharma beslutar om en fullt garanterad företrädesemission om cirka 2,5 mil…
Swedish 156.3 KB
2022-03-10 14:00
Delisting Announcement
Karo Pharma receives approval to delist the Company’s share from Nasdaq Stockho…
English 697.2 KB
2022-03-10 14:00
Delisting Announcement
Karo Pharma erhåller villkorat godkännande om avnotering av Bolagets aktier frå…
Swedish 696.0 KB
2022-03-09 12:00
Delisting Announcement
Karo Pharma applies for delisting of the Company’s shares from Nasdaq Stockholm…
English 51.0 KB
2022-03-09 12:00
Delisting Announcement
Karo Pharma ansöker om avnotering av Bolagets aktier från Nasdaq Stockholm i sa…
Swedish 51.7 KB

Automate Your Workflow. Get a real-time feed of all Karo Pharma AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Karo Pharma AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Karo Pharma AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
KalVista Pharmaceuticals, Inc. Logo
Developing oral protease inhibitors for rare diseases like hereditary angioedema (HAE).
United States of America KALV
Kamada Ltd. Logo
Develops specialty plasma-derived therapeutics for rare and serious conditions.
Israel KMDA
KAMADA LTD Logo
Develops specialty plasma-derived therapeutics for rare and serious diseases.
United States of America KMDA
KANABO GROUP PLC Logo
Develops cannabis formulas and vaporization devices for the medical and consumer wellness markets.
United Kingdom KNB
Kancera Logo
Develops small molecule drugs targeting the fractalkine axis for cancer and inflammatory diseases.
Sweden KAN
KANGSTEM BIOTECH CO., LTD. Logo
Develops stem cell therapies for rare diseases; offers culture media, cell platforms, and CDMO services.
South Korea 217730
Karyopharm Therapeutics Inc. Logo
Develops novel oral cancer therapies by inhibiting nuclear export for hard-to-treat tumors.
United States of America KPTI
KAZIA THERAPEUTICS LTD Logo
Oncology-focused drug development firm advancing anti-cancer candidates for brain cancers in trials.
United States of America KZIA
KBIO COMPANY Inc. Logo
Using a plant-based platform to rapidly develop biologics for public health.
South Korea 038530
Keeps Biopharma Inc. Logo
Develops cancer therapies and obesity drugs; manufactures industrial and cleanroom products.
South Korea 256940

Talk to a Data Expert

Have a question? We'll get back to you promptly.